Thomas Smith
Stock Analyst at Leerink Partners
(2.31)
# 2,618
Out of 4,911 analysts
67
Total ratings
29.51%
Success rate
14.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $0.37 | +172.48% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $2.31 | +289.61% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.68 | +316.67% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $3.86 | +651.30% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $13.36 | +191.92% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $10.20 | +154.90% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $80 | $12.65 | +532.41% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $69.76 | -71.33% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $591.74 | -26.49% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $60.64 | -40.63% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.35 | +197.87% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $18.32 | +14.63% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $17.49 | +157.29% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $7.84 | -23.47% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $4.08 | +47.06% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $1.07 | +367.29% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $55.03 | -69.11% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $23.22 | +175.62% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $18.76 | +273.13% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $9.97 | +190.87% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $3.73 | +597.05% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $33.50 | -64.18% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.98 | +151.19% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $3.80 | +10,420.78% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $14.38 | +456.33% | 2 | Dec 8, 2020 |
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.37
Upside: +172.48%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $2.31
Upside: +289.61%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.68
Upside: +316.67%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $3.86
Upside: +651.30%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $13.36
Upside: +191.92%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $10.20
Upside: +154.90%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $80
Current: $12.65
Upside: +532.41%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $69.76
Upside: -71.33%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $591.74
Upside: -26.49%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $60.64
Upside: -40.63%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.35
Upside: +197.87%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $18.32
Upside: +14.63%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $17.49
Upside: +157.29%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $7.84
Upside: -23.47%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $4.08
Upside: +47.06%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.07
Upside: +367.29%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $55.03
Upside: -69.11%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $23.22
Upside: +175.62%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $18.76
Upside: +273.13%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $9.97
Upside: +190.87%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $3.73
Upside: +597.05%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $33.50
Upside: -64.18%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.98
Upside: +151.19%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $3.80
Upside: +10,420.78%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $14.38
Upside: +456.33%